BACKGROUND: Although preclinical and epidemiological data suggest that statins may have antineoplastic properties, the impact of statin use on patient survival after a curative resection of stage III colon cancer is unknown. METHODS: We conducted a prospective observational study of 842 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial from April 1999 to May 2001 to investigate the relationship between statin use and survival. Disease-free survival (DFS), recurrence-free survival (RFS), and overall survival (OS) were investigated by Kaplan-Meier curves and log-rank tests in the overall study population and in a subset of patients stratified by KRAS mutation status (n = 394), and Cox proportional hazards regression was used to assess the simultaneous impact of confounding variables. All statistical tests were two-sided. RESULTS: Among 842 patients, 134 (15.9%) reported statin use after completing adjuvant chemotherapy. DFS among statin users and nonusers was similar (hazard ratio [HR] of cancer recurrence or death = 1.04, 95% confidence interval [CI] = 0.73 to 1.49). RFS and OS were also similar between statin users and nonusers (adjusted HR of cancer recurrence = 1.14, 95% CI = 0.77 to 1.69; adjusted HR of death = 1.15, 95% CI = 0.77 to 1.71). Survival outcomes were similar regardless of increasing duration of statin use before cancer diagnosis (P(trend) = .63, .63, and .59 for DFS, RFS, and OS, respectively). The impact of statin use did not differ by tumor KRAS mutation status, with similar DFS, RFS, and OS for statin use among mutant and wild-type subgroups (P(interaction) = .84, .67, and .98 for DFS, RFS, and OS, respectively). CONCLUSION: Statin use during and after adjuvant chemotherapy was not associated with improved DFS, RFS, or OS in patients with stage III colon cancer, regardless of KRAS mutation status.
RCT Entities:
BACKGROUND: Although preclinical and epidemiological data suggest that statins may have antineoplastic properties, the impact of statin use on patient survival after a curative resection of stage III colon cancer is unknown. METHODS: We conducted a prospective observational study of 842 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial from April 1999 to May 2001 to investigate the relationship between statin use and survival. Disease-free survival (DFS), recurrence-free survival (RFS), and overall survival (OS) were investigated by Kaplan-Meier curves and log-rank tests in the overall study population and in a subset of patients stratified by KRAS mutation status (n = 394), and Cox proportional hazards regression was used to assess the simultaneous impact of confounding variables. All statistical tests were two-sided. RESULTS: Among 842 patients, 134 (15.9%) reported statin use after completing adjuvant chemotherapy. DFS among statin users and nonusers was similar (hazard ratio [HR] of cancer recurrence or death = 1.04, 95% confidence interval [CI] = 0.73 to 1.49). RFS and OS were also similar between statin users and nonusers (adjusted HR of cancer recurrence = 1.14, 95% CI = 0.77 to 1.69; adjusted HR of death = 1.15, 95% CI = 0.77 to 1.71). Survival outcomes were similar regardless of increasing duration of statin use before cancer diagnosis (P(trend) = .63, .63, and .59 for DFS, RFS, and OS, respectively). The impact of statin use did not differ by tumorKRAS mutation status, with similar DFS, RFS, and OS for statin use among mutant and wild-type subgroups (P(interaction) = .84, .67, and .98 for DFS, RFS, and OS, respectively). CONCLUSION: Statin use during and after adjuvant chemotherapy was not associated with improved DFS, RFS, or OS in patients with stage III colon cancer, regardless of KRAS mutation status.
Authors: Douglas J Robertson; Anders Hammerich Riis; Søren Friis; Lars Pedersen; John A Baron; Henrik Toft Sørensen Journal: Clin Gastroenterol Hepatol Date: 2010-09-23 Impact factor: 11.382
Authors: S Sharma; N Kemeny; D P Kelsen; D Ilson; E O'Reilly; S Zaknoen; C Baum; P Statkevich; E Hollywood; Y Zhu; L B Saltz Journal: Ann Oncol Date: 2002-07 Impact factor: 32.976
Authors: Alex A Adjei; Ann Mauer; Laura Bruzek; Randolph S Marks; Shauna Hillman; Susan Geyer; Lorelei J Hanson; John J Wright; Charles Erlichman; Scott H Kaufmann; Everett E Vokes Journal: J Clin Oncol Date: 2003-05-01 Impact factor: 44.544
Authors: Patrick W J C Serruys; Pim de Feyter; Carlos Macaya; Norbert Kokott; Jacques Puel; Matthias Vrolix; Angelo Branzi; Marcelo C Bertolami; Graham Jackson; Bradley Strauss; Bernhard Meier Journal: JAMA Date: 2002-06-26 Impact factor: 56.272
Authors: Hannes Franz Alber; Jozef Dulak; Matthias Frick; Wolfgang Dichtl; Severin Paul Schwarzacher; Otmar Pachinger; Franz Weidinger Journal: J Am Coll Cardiol Date: 2002-06-19 Impact factor: 24.094
Authors: Jessica Chubak; Denise M Boudreau; Heidi S Wirtz; Barbara McKnight; Noel S Weiss Journal: J Natl Cancer Inst Date: 2013-08-12 Impact factor: 13.506
Authors: Shuji Ogino; Reiko Nishihara; Tyler J VanderWeele; Molin Wang; Akihiro Nishi; Paul Lochhead; Zhi Rong Qian; Xuehong Zhang; Kana Wu; Hongmei Nan; Kazuki Yoshida; Danny A Milner; Andrew T Chan; Alison E Field; Carlos A Camargo; Michelle A Williams; Edward L Giovannucci Journal: Epidemiology Date: 2016-07 Impact factor: 4.822
Authors: Samuel D Kaffenberger; Opal Lin-Tsai; Kelly L Stratton; Todd M Morgan; Daniel A Barocas; Sam S Chang; Michael S Cookson; S Duke Herrell; Joseph A Smith; Peter E Clark Journal: Urol Oncol Date: 2014-10-31 Impact factor: 3.498
Authors: Kaori Shima; Teppei Morikawa; Mai Yamauchi; Aya Kuchiba; Yu Imamura; Xiaoyun Liao; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino Journal: PLoS One Date: 2011-09-20 Impact factor: 3.240